2014
DOI: 10.1016/j.ygyno.2014.07.003
|View full text |Cite
|
Sign up to set email alerts
|

A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer

Abstract: Objective. To examine the tolerability and antitumor activity of trebananib plus pegylated liposomal doxorubicin (PLD) or topotecan in recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.Methods. In this open-label phase 1b study, patients received trebananib 10 mg/kg or 15 mg/kg IV QW plus PLD 50 mg/m 2 (cohorts A1 and A3, respectively) or topotecan 4 mg/m 2 (cohorts B1 and B3, respectively). Endpoints were dose-limiting toxicity (DLT; primary); treatment-emergent adverse events (AEs),… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
12
0

Year Published

2015
2015
2019
2019

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 20 publications
(13 citation statements)
references
References 37 publications
1
12
0
Order By: Relevance
“…TPT has been combined clinically with angiogenesis inhibitors bevacizumab or trabananib [ 21 , 22 ]. Such a strategy combines agents targeting two separate pathways (DNA replication and angiogenesis) important to cancer, without overlapping side effects so as not to limit dosage of either drug.…”
Section: Discussionmentioning
confidence: 99%
“…TPT has been combined clinically with angiogenesis inhibitors bevacizumab or trabananib [ 21 , 22 ]. Such a strategy combines agents targeting two separate pathways (DNA replication and angiogenesis) important to cancer, without overlapping side effects so as not to limit dosage of either drug.…”
Section: Discussionmentioning
confidence: 99%
“…20 Early clinical trials demonstrated encouraging antitumor activity of trebananib in patients with various types of solid tumors. [21][22][23][24] In the current phase 2 study, we evaluated intravenous trebananib (30 mg/kg weekly) administered as single agent and in combination with intravenous bevacizumab (10 mg/kg biweekly) for patients with recurrent glioblastoma. Circulating biomarkers of angiogenesis and inflammation were evaluated to explore potential biomarkers that could be used to enable rational patient selection in future studies.…”
Section: Introductionmentioning
confidence: 99%
“…Two phase I studies have shown that Trebananib in combination with liposomal doxorubicin, topotecan or paclitaxel carboplatin has some clinical effectiveness [39,40]. This was later confirmed by a phase III trial, the TRINOVA 1 study, where recurrent ca ovary with platinum free interval less than a year was randomized to single agent paclitaxel or combination with Trebananib.…”
Section: Trebananibmentioning
confidence: 95%